Additional file 2 of Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for lung adenocarcinoma

Additional file 2. Table S1. Genetic instruments of plasma proteins for MR analysis. MR: Mendelian randomization; SNP: single nucleotide polymorphism; chr: chromosome; pos: position; eaf: effect allele frequency; se: standard error. Table S2. MR results for plasma proteins significantly associated with LUAD after Bonferroni correction. MR: Mendelian randomization; LUAD: lung adenocarcinoma; SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval; PVE: proportion of variance explained. Table S3. MR results of proteome and LUAD. MR: Mendelian randomization; LUAD: lung adenocarcinoma; SNP: single nucleotide polymorphism; nSNPs: number of SNPs; se: standard error; OR: odds ratio; CI: confidence interval; IVW:inverse-variance-weighted. Table S4. Steiger filtering and reverse MR results of LUAD as exposure and proteome as outcome. MR: Mendelian randomization; LUAD: lung adenocarcinoma; SNP: single nucleotide polymorphism; nSNPs: number of SNPs; OR: odds ratio; CI: confidence interval; IVW:inversevariance-weighted. Table S5. Bayesian co-localization analysis on nine potential causal proteins. Druggable genes were divided into three tiers, including targets of approved drugs and drugs in clinical development (tier 1), proteins closely related to drug targets or with associated drug-like compounds (tier 2), and extracellular proteins and members of key drug-target families (tier 3). SNP: single nucleotide polymorphism. Table S6. Previously-reported genome-wide significant association of SNPs as genetic instruments of three potential causal proteins. SNP: single nucleotide polymorphism; chr: chromosome; se: standard error; N_samples: number of samples; N_cases: number of cases; N_controls: number of controls. Table S7. MR results of risk factors versus LUAD (GWAS from European population). MR: Mendelian randomization; LUAD: lung adenocarcinoma; GWAS: genome-wide association study; SNP: single nucleotide polymorphism; nSNPs: number of SNPs; se: standard error; OR: odds ratio; CI: confidence interval; IVW:inverse-variance-weighted. Table S8. MR results of proteome and LUAD risk factors. MR: Mendelian randomization; LUAD: lung adenocarcinoma; SNP: single nucleotide polymorphism; nSNPs: number of SNPs; se: standard error; OR: odds ratio; CI: confidence interval; IVW:inverse-variance-weighted; COPD: chronic obstructive pulmonary disease. Table S9. LUAD mediation results for protein targets on LUAD via risk factors. LUAD: lung adenocarcinoma. Table S10. Summary of druggability and drug development for LUAD associated with plasma proteins through MR analysis. Druggable genes were divided into three tiers, including targets of approved drugs and drugs in clinical development (tier 1), proteins closely related to drug targets or with associated drug-like compounds (tier 2), and extracellular proteins and members of key drug-target families (tier 3). LUAD: lung adenocarcinoma; NSCLC: non-small cell lung cancer.